Clavis intends to leverage its LVT technology to develop a strong pipeline of proprietary new and improved cancer drugs.
Clavis Pharma has chosen to focus its resources on oncology (cancer treatment), due to the large unmet medical need, relatively shorter time to market, and potentially lower cost of development.
The pharmaceutical oncology market represents the fourth largest and the fastest growing pharmaceutical market in the world, doubling in size to over USD 70 billion in 2010 over a six-year period (Datamonitor 2011). This growth is about two times that of the overall pharmaceutical market.
The attractive features of oncology include: Large market size, high expected growth, large unmet medical need, multiple opportunities offered by combination therapies, access to patients already in Phase I, accelerated or "fast track" regulatory pathways and high demand for licensed compounds from established pharmaceutical companies.
For published articles and posters see section Publications.
Advanced and Focused Oncology Pipeline
